Neuroprotective properties of GLP-1: theoretical and practical applications.
Identifieur interne : 000583 ( Hal/Checkpoint ); précédent : 000582; suivant : 000584Neuroprotective properties of GLP-1: theoretical and practical applications.
Auteurs : Jens Juul Holst [Danemark] ; Remy Burcelin [France] ; Esther Nathanson [États-Unis]Source :
- Current Medical Research and Opinion [ 0300-7995 ] ; 2011-03.
Abstract
In the past few years, the development of pharmaceutical agents that enhance the physiological effects of glucagon-like peptide-1 (GLP-1), either through GLP-1 receptor agonism (GLP-1 agonists) or by inhibiting GLP-1 degradation (dipeptidylpeptidase-4 inhibitors) has broadened the range of treatment options for individuals with type 2 diabetes. It has been recognized for some time that GLP-1 also has extra-pancreatic effects, notably targeting the brain, where it regulates appetite and satiety, as well as peripheral functions highly controlled by the autonomic nervous system, such as gastric emptying. Furthermore, data are beginning to emerge that indicate a potential role for GLP-1 in neuroprotection. The increased risk of Alzheimer's disease, Parkinson's disease and stroke in people with type 2 diabetes suggests that shared mechanisms/pathways of cell death, possibly related to insulin dysregulation, may underlie all of these disorders. Although the disease anatomy varies with each disorder, a wide range of genetic and environmental triggers result in activation of similar biochemical pathways in all of them, suggesting a complex network of biochemical events that feed in to a final common path towards cellular dysfunction and death. This article summarizes the evidence for neuronal activity of GLP-1 and examines the limited data that currently exist on the therapeutic potential of GLP-1 in specific neurological and neurodegenerative conditions, namely Alzheimer's disease, Parkinson's disease, Huntingdon's disease, stroke and peripheral sensory neuropathy.
Url:
DOI: 10.1185/03007995.2010.549466
Links toward previous steps (curation, corpus...)
Links to Exploration step
Hal:inserm-00615221Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective properties of GLP-1: theoretical and practical applications.</title><author><name sortKey="Holst, Jens Juul" sort="Holst, Jens Juul" uniqKey="Holst J" first="Jens Juul" last="Holst">Jens Juul Holst</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-164975" status="INCOMING"> <orgName>Department of Biomedical Sciences, The Panum Institute, University of Copenhagen</orgName> <desc> <address> <addrLine>Copenhagen</addrLine> <country key="DK"></country> </address> </desc> <listRelation> <relation active="#struct-301133" type="direct"></relation> </listRelation><tutelles><tutelle active="#struct-301133" type="direct"><org type="institution" xml:id="struct-301133" status="INCOMING"> <orgName>University of Copenhagen</orgName> <desc> <address> <country key="DK"></country> </address> </desc></org></tutelle></tutelles></hal:affiliation><country>Danemark</country></affiliation></author><author><name sortKey="Burcelin, Remy" sort="Burcelin, Remy" uniqKey="Burcelin R" first="Remy" last="Burcelin">Remy Burcelin</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-27489" status="OLD"> <orgName>Institut de médecine moléculaire de Rangueil</orgName> <orgName type="acronym">I2MR</orgName> <desc> <address> <addrLine>Institut Louis Bugnard 1, avenue Jean Poulhes BP 84225 31432 TOULOUSE CEDEX 4</addrLine> <country key="FR"></country> </address> </desc> <listRelation> <relation active="#struct-217752" type="direct"></relation> <relation active="#struct-300625" type="direct"></relation> <relation active="#struct-301493" type="direct"></relation> <relation name="U858" active="#struct-303623" type="direct"></relation> </listRelation><tutelles><tutelle active="#struct-217752" type="direct"><org type="institution" xml:id="struct-217752" status="VALID"> <orgName>Université Paul Sabatier - Toulouse 3</orgName> <orgName type="acronym">UPS</orgName> <desc> <address> <addrLine>118 route de Narbonne - 31062 Toulouse</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.univ-tlse3.fr/</ref> </desc></org></tutelle><tutelle active="#struct-300625" type="direct"><org type="institution" xml:id="struct-300625" status="VALID"> <orgName>IFR31</orgName> <desc> <address> <country key="FR"></country> </address> </desc></org></tutelle><tutelle active="#struct-301493" type="direct"><org type="institution" xml:id="struct-301493" status="VALID"> <orgName>IFR150</orgName> <desc> <address> <country key="FR"></country> </address> </desc></org></tutelle><tutelle name="U858" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc></org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author><author><name sortKey="Nathanson, Esther" sort="Nathanson, Esther" uniqKey="Nathanson E" first="Esther" last="Nathanson">Esther Nathanson</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-164977" status="INCOMING"> <orgName>Watermeadow Medical USA</orgName> <desc> <address> <addrLine>New York, NY</addrLine> <country key="US"></country> </address> </desc> <listRelation> <relation active="#struct-341817" type="direct"></relation> </listRelation><tutelles><tutelle active="#struct-341817" type="direct"><org type="institution" xml:id="struct-341817" status="INCOMING"> <orgName>Watermeadow Medical USA</orgName> <desc> <address> <country key="FR"></country> </address> </desc></org></tutelle></tutelles></hal:affiliation><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:inserm-00615221</idno><idno type="halId">inserm-00615221</idno><idno type="halUri">http://www.hal.inserm.fr/inserm-00615221</idno><idno type="url">http://www.hal.inserm.fr/inserm-00615221</idno><idno type="doi">10.1185/03007995.2010.549466</idno><date when="2011-03">2011-03</date><idno type="wicri:Area/Hal/Corpus">000793</idno><idno type="wicri:Area/Hal/Curation">000793</idno><idno type="wicri:Area/Hal/Checkpoint">000583</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000583</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroprotective properties of GLP-1: theoretical and practical applications.</title><author><name sortKey="Holst, Jens Juul" sort="Holst, Jens Juul" uniqKey="Holst J" first="Jens Juul" last="Holst">Jens Juul Holst</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-164975" status="INCOMING"> <orgName>Department of Biomedical Sciences, The Panum Institute, University of Copenhagen</orgName> <desc> <address> <addrLine>Copenhagen</addrLine> <country key="DK"></country> </address> </desc> <listRelation> <relation active="#struct-301133" type="direct"></relation> </listRelation><tutelles><tutelle active="#struct-301133" type="direct"><org type="institution" xml:id="struct-301133" status="INCOMING"> <orgName>University of Copenhagen</orgName> <desc> <address> <country key="DK"></country> </address> </desc></org></tutelle></tutelles></hal:affiliation><country>Danemark</country></affiliation></author><author><name sortKey="Burcelin, Remy" sort="Burcelin, Remy" uniqKey="Burcelin R" first="Remy" last="Burcelin">Remy Burcelin</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-27489" status="OLD"> <orgName>Institut de médecine moléculaire de Rangueil</orgName> <orgName type="acronym">I2MR</orgName> <desc> <address> <addrLine>Institut Louis Bugnard 1, avenue Jean Poulhes BP 84225 31432 TOULOUSE CEDEX 4</addrLine> <country key="FR"></country> </address> </desc> <listRelation> <relation active="#struct-217752" type="direct"></relation> <relation active="#struct-300625" type="direct"></relation> <relation active="#struct-301493" type="direct"></relation> <relation name="U858" active="#struct-303623" type="direct"></relation> </listRelation><tutelles><tutelle active="#struct-217752" type="direct"><org type="institution" xml:id="struct-217752" status="VALID"> <orgName>Université Paul Sabatier - Toulouse 3</orgName> <orgName type="acronym">UPS</orgName> <desc> <address> <addrLine>118 route de Narbonne - 31062 Toulouse</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.univ-tlse3.fr/</ref> </desc></org></tutelle><tutelle active="#struct-300625" type="direct"><org type="institution" xml:id="struct-300625" status="VALID"> <orgName>IFR31</orgName> <desc> <address> <country key="FR"></country> </address> </desc></org></tutelle><tutelle active="#struct-301493" type="direct"><org type="institution" xml:id="struct-301493" status="VALID"> <orgName>IFR150</orgName> <desc> <address> <country key="FR"></country> </address> </desc></org></tutelle><tutelle name="U858" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc></org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author><author><name sortKey="Nathanson, Esther" sort="Nathanson, Esther" uniqKey="Nathanson E" first="Esther" last="Nathanson">Esther Nathanson</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-164977" status="INCOMING"> <orgName>Watermeadow Medical USA</orgName> <desc> <address> <addrLine>New York, NY</addrLine> <country key="US"></country> </address> </desc> <listRelation> <relation active="#struct-341817" type="direct"></relation> </listRelation><tutelles><tutelle active="#struct-341817" type="direct"><org type="institution" xml:id="struct-341817" status="INCOMING"> <orgName>Watermeadow Medical USA</orgName> <desc> <address> <country key="FR"></country> </address> </desc></org></tutelle></tutelles></hal:affiliation><country>États-Unis</country></affiliation></author></analytic><idno type="DOI">10.1185/03007995.2010.549466</idno><series><title level="j">Current Medical Research and Opinion</title><idno type="ISSN">0300-7995</idno><imprint><date type="datePub">2011-03</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the past few years, the development of pharmaceutical agents that enhance the physiological effects of glucagon-like peptide-1 (GLP-1), either through GLP-1 receptor agonism (GLP-1 agonists) or by inhibiting GLP-1 degradation (dipeptidylpeptidase-4 inhibitors) has broadened the range of treatment options for individuals with type 2 diabetes. It has been recognized for some time that GLP-1 also has extra-pancreatic effects, notably targeting the brain, where it regulates appetite and satiety, as well as peripheral functions highly controlled by the autonomic nervous system, such as gastric emptying. Furthermore, data are beginning to emerge that indicate a potential role for GLP-1 in neuroprotection. The increased risk of Alzheimer's disease, Parkinson's disease and stroke in people with type 2 diabetes suggests that shared mechanisms/pathways of cell death, possibly related to insulin dysregulation, may underlie all of these disorders. Although the disease anatomy varies with each disorder, a wide range of genetic and environmental triggers result in activation of similar biochemical pathways in all of them, suggesting a complex network of biochemical events that feed in to a final common path towards cellular dysfunction and death. This article summarizes the evidence for neuronal activity of GLP-1 and examines the limited data that currently exist on the therapeutic potential of GLP-1 in specific neurological and neurodegenerative conditions, namely Alzheimer's disease, Parkinson's disease, Huntingdon's disease, stroke and peripheral sensory neuropathy.</div></front></TEI><hal api="V3"> <titleStmt> <title xml:lang="en">Neuroprotective properties of GLP-1: theoretical and practical applications.</title> <author role="crp"> <persName> <forename type="first">Jens Juul</forename> <surname>Holst</surname> </persName> <email type="md5">222dd5b955c5bf61cf1971b2b11b5655</email> <email type="domain">sund.ku.dk</email> <idno type="halauthorid">633666</idno> <affiliation ref="#struct-164975"></affiliation> </author> <author role="aut"> <persName> <forename type="first">Remy</forename> <surname>Burcelin</surname> </persName> <idno type="halauthorid">426311</idno> <affiliation ref="#struct-27489"></affiliation> </author> <author role="aut"> <persName> <forename type="first">Esther</forename> <surname>Nathanson</surname> </persName> <idno type="halauthorid">633667</idno> <affiliation ref="#struct-164977"></affiliation> </author> <editor role="depositor"> <persName> <forename>Marie Francoise</forename> <surname>Simon</surname> </persName> <email type="md5">8ea1139230ec722c2221baad7d89e5e5</email> <email type="domain">inserm.fr</email> </editor> </titleStmt> <editionStmt> <edition n="v1" type="current"> <date type="whenSubmitted">2011-08-18 12:10:58</date> <date type="whenModified">2011-08-24 10:29:11</date> <date type="whenReleased">2011-08-24 10:29:11</date> <date type="whenProduced">2011-03</date> </edition> <respStmt> <resp>contributor</resp> <name key="118088"> <persName> <forename>Marie Francoise</forename> <surname>Simon</surname> </persName> <email type="md5">8ea1139230ec722c2221baad7d89e5e5</email> <email type="domain">inserm.fr</email> </name> </respStmt> </editionStmt> <publicationStmt> <distributor>CCSD</distributor> <idno type="halId">inserm-00615221</idno> <idno type="halUri">http://www.hal.inserm.fr/inserm-00615221</idno> <idno type="halBibtex">holst:inserm-00615221</idno> <idno type="halRefHtml">Current Medical Research and Opinion, Taylor & Francis, 2011, 27 (3), pp.547-58. <10.1185/03007995.2010.549466></idno> <idno type="halRef">Current Medical Research and Opinion, Taylor & Francis, 2011, 27 (3), pp.547-58. <10.1185/03007995.2010.549466></idno> </publicationStmt> <seriesStmt> <idno type="stamp" n="INSERM">INSERM - Institut national de la santé et de la recherche médicale</idno> <idno type="stamp" n="UNIV-TLSE3">Université Paul Sabatier - Toulouse III</idno> </seriesStmt> <notesStmt> <note type="audience" n="2">International</note> <note type="popular" n="0">No</note> <note type="peer" n="1">Yes</note> </notesStmt> <sourceDesc> <biblStruct> <analytic> <title xml:lang="en">Neuroprotective properties of GLP-1: theoretical and practical applications.</title> <author role="crp"> <persName> <forename type="first">Jens Juul</forename> <surname>Holst</surname> </persName> <email type="md5">222dd5b955c5bf61cf1971b2b11b5655</email> <email type="domain">sund.ku.dk</email> <idno type="halauthorid">633666</idno> <affiliation ref="#struct-164975"></affiliation> </author> <author role="aut"> <persName> <forename type="first">Remy</forename> <surname>Burcelin</surname> </persName> <idno type="halauthorid">426311</idno> <affiliation ref="#struct-27489"></affiliation> </author> <author role="aut"> <persName> <forename type="first">Esther</forename> <surname>Nathanson</surname> </persName> <idno type="halauthorid">633667</idno> <affiliation ref="#struct-164977"></affiliation> </author> </analytic> <monogr> <idno type="halJournalId" status="VALID">12265</idno> <idno type="issn">0300-7995</idno> <idno type="eissn">1473-4877</idno> <title level="j">Current Medical Research and Opinion</title> <imprint> <publisher>Taylor & Francis</publisher> <biblScope unit="volume">27</biblScope> <biblScope unit="issue">3</biblScope> <biblScope unit="pp">547-58</biblScope> <date type="datePub">2011-03</date> </imprint> </monogr> <idno type="doi">10.1185/03007995.2010.549466</idno> <idno type="pubmed">21222567</idno> </biblStruct> </sourceDesc> <profileDesc> <langUsage> <language ident="en">English</language> </langUsage> <textClass> <classCode scheme="mesh">Animals</classCode> <classCode scheme="mesh">Diabetes Complications</classCode> <classCode scheme="mesh">Glucagon-Like Peptide 1</classCode> <classCode scheme="mesh">Humans</classCode> <classCode scheme="mesh">Models, Biological</classCode> <classCode scheme="mesh">Models, Theoretical</classCode> <classCode scheme="mesh">Nervous System</classCode> <classCode scheme="mesh">Nervous System Diseases</classCode> <classCode scheme="mesh">Neuroprotective Agents</classCode> <classCode scheme="halTypology" n="ART">Journal articles</classCode> </textClass> <abstract xml:lang="en">In the past few years, the development of pharmaceutical agents that enhance the physiological effects of glucagon-like peptide-1 (GLP-1), either through GLP-1 receptor agonism (GLP-1 agonists) or by inhibiting GLP-1 degradation (dipeptidylpeptidase-4 inhibitors) has broadened the range of treatment options for individuals with type 2 diabetes. It has been recognized for some time that GLP-1 also has extra-pancreatic effects, notably targeting the brain, where it regulates appetite and satiety, as well as peripheral functions highly controlled by the autonomic nervous system, such as gastric emptying. Furthermore, data are beginning to emerge that indicate a potential role for GLP-1 in neuroprotection. The increased risk of Alzheimer's disease, Parkinson's disease and stroke in people with type 2 diabetes suggests that shared mechanisms/pathways of cell death, possibly related to insulin dysregulation, may underlie all of these disorders. Although the disease anatomy varies with each disorder, a wide range of genetic and environmental triggers result in activation of similar biochemical pathways in all of them, suggesting a complex network of biochemical events that feed in to a final common path towards cellular dysfunction and death. This article summarizes the evidence for neuronal activity of GLP-1 and examines the limited data that currently exist on the therapeutic potential of GLP-1 in specific neurological and neurodegenerative conditions, namely Alzheimer's disease, Parkinson's disease, Huntingdon's disease, stroke and peripheral sensory neuropathy.</abstract> </profileDesc> </hal></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Hal/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000583 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Hal/Checkpoint/biblio.hfd -nk 000583 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Hal
|étape= Checkpoint
|type= RBID
|clé= Hal:inserm-00615221
|texte= Neuroprotective properties of GLP-1: theoretical and practical applications.
}}
| This area was generated with Dilib version V0.6.29. |  |